All relevant data are within the paper.

Introduction {#sec005}
============

Lung transplantation is an effective therapeutic option for patients with end-stage lung diseases. However, the 5-year survival rate for adult lung transplant recipients is approximately 60%, according to the registry report of the International Society for Heart and Lung Transplantation (ISHLT). \[[@pone.0233804.ref001]\] The survival rate is still lower compared to the transplantation of other organs. We often must utilize lung grafts from marginal donors with localized pneumonia or lung contusion because we are faced with a severe donor shortage. \[[@pone.0233804.ref002]\] Chest CT scans of such donors are important for the assessment of the lung graft and useful for subsequent postoperative management of the recipient. However, chest CT scans taken immediately before the lung retrieval are not available in most cases because it is not always possible to take chest CT scans of a brain-dead donor at the hospital.

Verleden et al. reported CT scans of frozen whole lungs that were declined for transplantation due to allograft-related or non--allograft-related reasons. Interestingly, in their study, 4 of 8 cases showed CT alterations, whereas they were declined due to non-allograft-related reasons. \[[@pone.0233804.ref003]\] We developed an ex vivo lung CT (EVL-CT) technique that can be performed as part of the clinal practice because it is very simple and requires only a few minutes. This technique allows us to obtain detailed CT images and morphologically assess the already retrieved lung using an ex vivo method. However, the usefulness of EVL-CT in lung transplantation is still unknown. The objective of this study was to investigate correlations between the EVL-CT findings and post-transplant outcome in patients who underwent bilateral lung transplantation (BLT) or single lung transplantation (SLT).

Patients and methods {#sec006}
====================

EVL-CT technique {#sec007}
----------------

When we recovered a lung graft from a brain-dead donor, we inflate it with a sustained airway pressure of 15--20 cmH~2~O and a fraction of inspiratory oxygen of 50%. Then, we transport the lung graft to Tohoku University Hospital for the following lung transplant surgery. Immediately after arriving at the hospital, the lung graft is transferred to the medical imaging center and CT images of 1.25-mm-thick slice are obtained by BrightSpeed Elite (GE Healthcare Japan Ltd, Tokyo, Japan). Routine helical CT scans of whole lung are performed at a peak tube voltage of 120 kVp, with a variable mAs setting using an automatic exposure control system ([Fig 1A and 1B](#pone.0233804.g001){ref-type="fig"}). Only 3 minutes are required for EVL-CT.

![Ex vivo donor lung CT technique.\
After the retrieval of the lung graft from a brain-dead donor, we transported it to our hospital. Immediately after arriving at the hospital, the lung graft was transferred to the medical imaging center and CT images were obtained. (A) Overall view of the CT machine and the lung graft. (B) Close view of the lung graft in a plastic bag on the CT table.](pone.0233804.g001){#pone.0233804.g001}

After EVL-CT, lungs are implanted into the recipients by the usual surgical procedure. When we performed EVL-CT in the present study, the recipient was already under anesthesia and the lung transplant surgery was ongoing. In our current practice, we do not decide the availability of the lung graft based on the EVL-CT data.

Patients and study groups {#sec008}
-------------------------

EVL-CT data from cases since October 2007 are available. Since then, EVL-CT was done in all lung transplant cases except living-donor lung transplant cases. We retrospectively reviewed the records of 92 patients who underwent lung transplantation between October 2007 and September 2017. We excluded living-donor lung transplantations (10 cases), lobar lung transplantations (6 cases) and retransplantations (6 cases) from this study. Ultimately, 70 patients with available EVL-CT data who underwent BLT or SLT were included in this study. Thirty-four BLT cases and 36 SLT cases were included ([Fig 2](#pone.0233804.g002){ref-type="fig"}).

![Consort flow diagram indicating subject inclusion.\
EVL-CT, ex vivo lung CT. BLT, bilateral lung transplantation. SLT, single lung transplantation.](pone.0233804.g002){#pone.0233804.g002}

The recipients were divided into 2 groups according to the findings of EVL-CT of the lung graft in SLT and BLT, respectively. Recipients in the control group were transplanted lung grafts without any infiltrates (control group, [Fig 3A, 3B and 3C](#pone.0233804.g003){ref-type="fig"}). Recipients in the infiltration group received lung grafts with infiltrates (infiltration group, [Fig 4A, 4B, 4C and 4D](#pone.0233804.g004){ref-type="fig"}). The CT readers were trained using images of typical cases from a pilot study. EVL-CT images of each case were interpreted by two radiologists and a thoracis surgeon (H.O.) who were blinded to the donor data. With a consistent diagnosis by 2 of 3 CT readers, the recipient was divided into the control or infiltration group.

![Ex vivo donor lung CT images of a case from the bilateral lung transplantation (BLT) control group.\
CT images show no infiltrate in the lung graft. (A, B) Transaxial CT images of the lung graft. (C) A coronal image of the lung graft.](pone.0233804.g003){#pone.0233804.g003}

![Ex vivo donor lung CT images of a case from the bilateral lung transplantation (BLT) infiltration group.\
CT images show infiltrates in the left lower lobe of the lung graft. (A, B) Transaxial CT images of the lung graft. (C) A coronal image of the lung graft. (D) A sagittal image of the lung graft.](pone.0233804.g004){#pone.0233804.g004}

The other collected data included the demographics of donors and the pre-transplant demographics of the recipients, surgical characteristics, period of mechanical ventilation and ICU stay, complications, morbidity, mortality and the survival rate after lung transplantation. The data were compared between the control and the infiltration group in SLT and BLT, respectively. In the BLT cases, primary graft dysfunction (PGD) was graded according to the International Society for Heart and Lung Transplantation classification (ISHLT). \[[@pone.0233804.ref004]\] (PGD was not graded in the SLT cases because PGD grading with the classification is not always accurate in SLT cases due to the function of the native lung on the other side).

Japan Organ Transplant Network obtained consent for the recovery of lung grafts. If the individual's intentions are unclear, his/her organs can now be donated with family consent. The Institutional Review Board of Tohoku University Hospital approved the study (No. 2018-1-125) and the research was conducted in accordance with the 2000 Declaration of Helsinki and the Declaration of Istanbul 2008. All patients gave written informed consent for EVL-CT and data collection.

Statistical analysis {#sec009}
--------------------

Data are expressed as mean ± standard deviation for normally distributed data and Student's *t*-test was used. Data are expressed as median with range for non-normally distributed data and the Mann-Whitney *U* test was used. Fisher's exact test or the chi-square test was performed for categorical values. The PGD grade at each time point was analyzed by repeated measures two-way ANOVA. Prism 5 (GraphPad Software Inc., La Jolla, CA) was used to perform these statistical analyses. Values of *p* \< 0.05 were regarded as significant. We did not perform sample size calculations because the present study is an exploratory research.

Results {#sec010}
=======

In 23 of 34 BLT cases (67.6%), EVL-CT showed no infiltrate in the lung graft (BLT control group). On the other hand, EVL-CT displayed infiltrates in the lung graft in 11 cases (32.4%, BLT infiltration group). There were 26 cases in the SLT control group (72.2%) and 10 cases in the SLT infiltration group (27.8%) ([Fig 2](#pone.0233804.g002){ref-type="fig"}). Structural lung diseases, such as emphysema and interstitial lung disease, were not detected in any cases in the present study.

[Table 1](#pone.0233804.t001){ref-type="table"} shows the demographics of the donors in each group in BLT. In most of the cases (73.9% in the BLT control group, 72.7% in the BLT infiltration group), there was no available chest CT image within 3 days before retrieval. Preretrieval CT showed infiltrates in the lung graft in 4 cases in the BLT control group and these infiltrates all seem to be small atelectasis. There was no significant difference in any parameters between the two groups except in the bronchial aspirates in the culture. The percentage of positive bronchial aspirates in the culture was significantly higher in the BLT infiltration group. Methicillin-susceptible staphylococcus aureus was the most frequently detected microorganism in the BLT infiltration group.

10.1371/journal.pone.0233804.t001

###### Demographics of the donors in bilateral lung transplantation.

![](pone.0233804.t001){#pone.0233804.t001g}

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                    BLT[^a^](#t001fn002){ref-type="table-fn"} control group\   BLT infiltration group\   *P* value
                                                                    (N = 23)                                                   (N = 11)                  
  ----------------------------------------------------------------- ---------------------------------------------------------- ------------------------- -----------
  Donor age (years)                                                 43.7 ± 13.5 (6--63)                                        38.4 ± 17.1 (11--62)      0.35

  Donor gender (M/F)                                                10 / 13                                                    6 / 5                     0.72

  Donor height (cm)                                                 161.2 ± 11.2 (125--175)                                    165.7 ± 10.3 (150--184)   0.29

  Donor weight (kg)                                                 56.8 ± 12.3 (37.0--67.7)                                   62.6 ± 17.4 (43--73.3)    0.29

  Donor BMI (kg/m^2^)[^b^](#t001fn003){ref-type="table-fn"}         21.6 ± 3.7 (12.8--31.6)                                    22.5 ± 4.5 (18.1--34.6)   0.58

  Preretrieval CXR[^c^](#t001fn004){ref-type="table-fn"} findings                                                                                        0.08

   Infiltration                                                     3 (13.0%)                                                  5 (45.5%)                 

   No infiltration                                                  20 (87.0%)                                                 6 (54.5%)                 

  Preretrieval CT images[^d^](#t001fn005){ref-type="table-fn"}                                                                                           1.00

   Unavailable                                                      17 (73.9%)                                                 8 (72.7%)                 

   Available                                                        6 (26.1%)                                                  3 (27.3%)                 

    Infiltration                                                    4 (66.7%)                                                  3 (100%)                  

    No infiltration                                                 2 (33.3%)                                                  0 (0%)                    

  Smoking history (pack-years)                                                                                                                           0.39

   None                                                             11 (47.8%)                                                 7 (63.6%)                 

   0--20                                                            7 (30.4%)                                                  1 (9.1%)                  

   20 ≤                                                             5 (21.7%)                                                  3 (27.3%)                 

  PaO~2~ / FiO~2~ (mmHg)                                            510 ± 80 (293--612)                                        478 ± 67 (335--545)       0.27

  Cause of brain death                                                                                                                                   0.83

   Cerebrovascular accident                                         11 (47.8%)                                                 5 (45.5%)                 

   Head trauma                                                      7 (30.4%)                                                  3 (27.3%)                 

   Brain ischemia                                                   4 (17.4%)                                                  3 (27.3%)                 

   Others                                                           1 (4.3%)                                                   0 (0%)                    

  Bronchial aspirates culture                                                                                                                            **0.004**

   Negative                                                         17 (73.9%)                                                 2 (18.2%)                 

   Positive                                                         6 (26.1%)                                                  9 (81.8%)                 

    MSSA[^e^](#t001fn006){ref-type="table-fn"}                      1 (4.3%)                                                   4 (36.4%)                 

    Candida species                                                 2 (8.7%)                                                   3 (27.3%)                 

    Coagulase-negative staphylococci                                0 (0%)                                                     2 (18.2%)                 

    Pseudomonas aeruginosa                                          0 (0%)                                                     2 (18.2%)                 

    Others                                                          3 (13.0%)                                                  2 (18.2%)                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as group mean ± standard deviation or number (%).

^a^BLT, bilateral lung transplantation.

^b^BMI, body mass index.

^c^Chest X-ray.

^d^CT images taken within 3 days.

^e^MSSA, methicillin-susceptible staphylococcus aureus.

[Table 2](#pone.0233804.t002){ref-type="table"} shows the demographics of the donors in each group in SLT. Similarly to the cases in BLT, in most of the cases (65.4% in the SLT control group, 80.0% in the SLT infiltration group) there was no available chest CT image within 3 days before retrieval. The percentage of positive bronchial aspirates in the culture was significantly higher in the SLT infiltration group.

10.1371/journal.pone.0233804.t002

###### Demographics of the donors in single lung transplantation.

![](pone.0233804.t002){#pone.0233804.t002g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                    SLT[^a^](#t002fn002){ref-type="table-fn"} control group\   SLT infiltration group\    *P* value
                                                                    (N = 26)                                                   (N = 10)                   
  ----------------------------------------------------------------- ---------------------------------------------------------- -------------------------- -----------
  Donor age (years)                                                 45.7 ± 12.6 (24--68)                                       40.0 ± 12.6 (18--56)       0.24

  Donor gender (M/F)                                                7 / 19                                                     6 / 4                      0.12

  Donor height (cm)                                                 158.8 ± 7.4 (147--177)                                     162.4 ± 6.7 (151--170)     0.25

  Donor weight (kg)                                                 51.3 ± 12.8 (31.6--73.0)                                   49.6 ± 13.3 (32.3--69.7)   0.73

  Donor BMI[^b^](#t002fn003){ref-type="table-fn"} (kg/m^2^)         20.4 ± 5.3 (13.7--31.1)                                    18.6 ± 4.0 (13.3--24.8)    0.35

  Preretrieval CXR[^c^](#t002fn004){ref-type="table-fn"} findings                                                                                         **0.002**

   Infiltration                                                     2 (7.7%)                                                   6 (60.0%)                  

   No infiltration                                                  24 (92.3%)                                                 4 (40.0%)                  

  Preretrieval CT images[^d^](#t002fn005){ref-type="table-fn"}                                                                                            0.69

   Unavailable                                                      17 (65.4%)                                                 8 (80.0%)                  

   Available                                                        9 (34.6%)                                                  2 (20.0%)                  

    Infiltration                                                    0 (0%)                                                     2 (100.0%)                 

    No infiltration                                                 9 (100.0%)                                                 0 (0%)                     

  Smoking history (pack-years)                                                                                                                            0.89

   None                                                             11 (42.3%)                                                 5 (50.0%)                  

   0--20                                                            10 (38.5%)                                                 3 (30.0%)                  

   20 ≤                                                             5 (19.2%)                                                  2 (20.0%)                  

  PaO~2~ / FiO~2~ (mmHg)                                            464 ± 97 (237--606)                                        423 ± 116 (187--576)       0.27

  Cause of brain death                                                                                                                                    

   Cerebrovascular accident                                         14 (53.8%)                                                 7 (70.0%)                  

   Brain ischemia                                                   8 (30.8%)                                                  2 (20.0%)                  

   Head trauma                                                      1 (3.8%)                                                   1 (10.0%)                  

   Others                                                           3 (11.6%)                                                  0 (0%)                     

  Bronchial aspirates culture                                                                                                                             **0.001**

   Negative                                                         21 (80.8%)                                                 2 (20.0%)                  

   Positive                                                         5 (19.2%)                                                  8 (80.0%)                  

    MSSA[^e^](#t002fn006){ref-type="table-fn"}                      1 (3.8%)                                                   4 (40.0%)                  

    Candida species                                                 3 (11.5%)                                                  3 (30.0%)                  

    Klebsiella pneumonia                                            0 (0%)                                                     3 (30.0%)                  

    MRSA[^f^](#t002fn007){ref-type="table-fn"}                      1 (3.8%)                                                   2 (20.0%)                  

    Corynebacterium species                                         2 (7.7%)                                                   0 (0%)                     

    Others                                                          3 (11.5%)                                                  5 (50.0%)                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as group mean ± standard deviation or number (%).

^a^SLT, single lung transplantation.

^b^BMI, body mass index.

^c^Chest X-ray.

^d^CT images taken within 3 days.

^e^MSSA, methicillin-susceptible staphylococcus aureus.

^f^MRSA, methicillin-resistant staphylococcus aureus.

Tables [3](#pone.0233804.t003){ref-type="table"} and [4](#pone.0233804.t004){ref-type="table"} show the pre-transplant demographics of the recipients in each group in BLT or SLT, respectively. There was no significant difference in any parameters between the two groups in both BLT and SLT. Tables [5](#pone.0233804.t005){ref-type="table"} and [6](#pone.0233804.t006){ref-type="table"} show the surgical characteristics in each group in BLT or SLT, respectively. Operative time, cold ischemic time and extracorporeal circulation use were similar between the control and infiltration groups in both BLT and SLT. The amount of intra-operative blood loss tended to be larger in the infiltration group in BLT.

10.1371/journal.pone.0233804.t003

###### Pre-transplant demographics of recipients in bilateral lung transplantation.

![](pone.0233804.t003){#pone.0233804.t003g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                  BLT[^a^](#t003fn002){ref-type="table-fn"} control group\   BLT infiltration group\   *P* value
                                                                  (N = 23)                                                   (N = 11)                  
  --------------------------------------------------------------- ---------------------------------------------------------- ------------------------- -----------
  Time on waitlist (days)                                         1180 ± 869 (11--4081)                                      1137 ± 538 (470--2016)    0.89

  Age (years)                                                     37.4 ± 13.5 (14--55)                                       39.9 ± 9.5 (22--51)       0.62

  Gender (M/F)                                                    9 / 14                                                     5 / 6                     1.00

  Height (cm)                                                     158.5 ± 10.0 (135--170)                                    162.3 ± 5.7 (155--176)    0.27

  Weight (kg)                                                     45.4 ± 9.3 (29--58)                                        51.7 ± 12.7 (37--77)      0.16

  BMI (kg/m^2^)[^b^](#t003fn003){ref-type="table-fn"}             18.0 ± 3.3 (12.3--25.4)                                    19.5 ± 4.0 (13.6--27.7)   0.28

  Indication                                                                                                                                           0.94

   IPAH[^c^](#t003fn004){ref-type="table-fn"}                     8 (34.8%)                                                  3 (27.3%)                 

   Bronchiectasis and DPB[^d^](#t003fn005){ref-type="table-fn"}   5 (21.7%)                                                  3 (27.3%)                 

   PH-not IPAH[^e^](#t003fn006){ref-type="table-fn"}              3 (13.0%)                                                  2 (18.2%)                 

   Others                                                         7 (30.4%)                                                  3 (27.3%)                 
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as group mean ± standard deviation or number (%).

^a^BLT, bilateral lung transplantation.

^b^BMI, body mass index.

^c^IPAH, idiopathic pulmonary arterial hypertension.

^d^DPB, diffuse panbronchiolitis.

^e^PH-not IPAH, pulmonary hypertension that is not IPAH.

10.1371/journal.pone.0233804.t004

###### Pre-transplant demographics of recipients in single lung transplantation.
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  -------------------------------------------------------------------------------------------------------------------------------------------------------
                                                        SLT[^a^](#t004fn002){ref-type="table-fn"} control group\   SLT infiltration group\    *P* value
                                                        (N = 26)                                                   (N = 10)                   
  ----------------------------------------------------- ---------------------------------------------------------- -------------------------- -----------
  Time on waitlist (days)                               946 ± 658 (193--3335)                                      892 ± 531 (252--1878)      0.82

  Age (years)                                           45.4 ± 10.1 (29--61)                                       47.1 ± 10.4 (23--61)       0.67

  Gender (M/F)                                          5 / 21                                                     5 / 5                      0.10

  Height (cm)                                           158.8 ± 7.4 (147--177)                                     162.4 ± 6.7 (151--170)     0.19

  Weight (kg)                                           51.4 ± 12.7 (31.6--73)                                     49.6 ± 13.3 (32.3--69.7)   0.71

  BMI (kg/m^2^)[^b^](#t004fn003){ref-type="table-fn"}   20.5 ± 5.3 (13.7--31.1)                                    18.6 ± 4.0 (13.3--24.8)    0.33

  Indication                                                                                                                                  0.54

   LAM[^c^](#t004fn004){ref-type="table-fn"}            15 (57.7%)                                                 4 (40.0%)                  

   IPF[^d^](#t004fn005){ref-type="table-fn"}            4 (15.4%)                                                  3 (30.0%)                  

   COPD[^e^](#t004fn006){ref-type="table-fn"}           2 (7.7%)                                                   1 (10.0%)                  

   CTD-IP[^f^](#t004fn007){ref-type="table-fn"}         2 (7.7%)                                                   1 (10.0%)                  

   Others                                               3 (11.5%)                                                  1 (10.0%)                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as group mean ± standard deviation or number (%).

^a^SLT, single lung transplantation.

^b^BMI, body mass index.

^c^LAM, lymphangioleiomyomatosis.

^d^IPF, idiopathic pulmonary fibrosis.

^e^COPD, chronic obstructive pulmonary disease.

^f^CTD-IP, collagen tissue disease-associated interstitial pneumonia.

10.1371/journal.pone.0233804.t005

###### Surgical characteristics in bilateral lung transplantation.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------
                                                             BLT[^a^](#t005fn002){ref-type="table-fn"} control group\   BLT infiltration group\   *P* value
                                                             (N = 23)                                                   (N = 11)                  
  ---------------------------------------------------------- ---------------------------------------------------------- ------------------------- -----------
  Operative time (min)                                       904 ± 197 (576--1439)                                      999 ± 238 (798--1531)     0.24

  Cold ischemic time                                                                                                                              

   1st lung (min)                                            543 ± 134 (244--792)                                       557 ± 87 (473--785)       0.76

   2nd lung (min)                                            701 ± 91 (550--870)                                        743 ± 45 (656--829)       0.17

  Extracorporeal circulation use                                                                                                                  

   CPB[^b^](#t005fn003){ref-type="table-fn"} or CPB + ECMO   14 (60.9%)                                                 6 (54.5%)                 

   ECMO[^c^](#t005fn004){ref-type="table-fn"}                6 (26.1%)                                                  5 (45.5%)                 

   No                                                        3 (13.0%)                                                  0 (0%)                    

  Intra-operative blood loss (ml)                            6841 ± 5537                                                13666 ± 14681             0.07

                                                             (289--15672)                                               (837--47429)              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as group mean ± standard deviation or number (%).

^a^BLT, bilateral lung transplantation.

^b^CPB, cardio-pulmonary bypass.

^c^ECMO, extracorporeal membrane oxygenation.

10.1371/journal.pone.0233804.t006

###### Surgical characteristics in single lung transplantation.
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  ----------------------------------------------------------------------------------------------------------------------------------------------
                                                SLT[^a^](#t006fn002){ref-type="table-fn"} control group\   SLT infiltration group\   *P* value
                                                (N = 26)                                                   (N = 10)                  
  --------------------------------------------- ---------------------------------------------------------- ------------------------- -----------
  Operative time (min)                          405 ± 89 (243--598)                                        411 ± 61 (298--503)       0.84

  Cold ischemic time (min)                      457 ± 48 (389--572)                                        477 ± 65 (361--583)       0.34

  Extracorporeal circulation use                                                                                                     

   CPB[^b^](#t006fn003){ref-type="table-fn"}    1 (3.8%)                                                   0 (0%)                    

   ECMO[^c^](#t006fn004){ref-type="table-fn"}   14 (53.8%)                                                 6 (60.0%)                 

   No                                           11 (42.3%)                                                 4 (40.0%)                 

  Intra-operative blood loss (ml)               1165 ± 1995                                                2102 ± 2823               0.29

                                                (116--10354)                                               (79--8750)                
  ----------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as group mean ± standard deviation or number (%).

^a^SLT, single lung transplantation.

^b^CPB, cardio-pulmonary bypass.

^c^ECMO, extracorporeal membrane oxygenation.

[Fig 5](#pone.0233804.g005){ref-type="fig"} shows the EVL-CT and post-transplant chest CT images of a typical lung transplant case in the BLT infiltration group. The recipient was diagnosed with emphysema and was on the waitlist for lung transplantation for 3 years. The lung graft was donated from a brain-dead donor with intracerebral hemorrhage. No infiltrate was mentioned in the chest X-ray of the donor taken immediately before retrieval. However, the EVL-CT of the graft demonstrated infiltrates in the left lower lobe ([Fig 5A and 5B](#pone.0233804.g005){ref-type="fig"}). The bronchial aspirates in the culture of the donor were positive for pseudomonas aeruginosa. We presumed that the donor had pneumonia caused by pseudomonas aeruginosa. One week after the transplant, the chest CT scans of the recipients revealed that infiltrates remained in the left lower lobe ([Fig 5C](#pone.0233804.g005){ref-type="fig"}). Because we already knew that infiltrates resulted from pneumonia of the donor, we continued the administration of effective antibiotics and the infiltrates gradually disappeared over time ([Fig 5D, 5E and 5F](#pone.0233804.g005){ref-type="fig"}).

![Ex vivo donor lung CT and post-transplant chest CT images of a typical lung transplant case in the bilateral lung transplantation (BLT) infiltration group.\
(A, B) Transaxial and coronal CT images of ex vivo lung CT (EVL-CT) show infiltrates in the left lower lobe. The arrow indicates infiltrates in the superior segment. (C) The infiltrates remained at one week post-transplant. (D, E, F) The infiltrates gradually disappeared over time.](pone.0233804.g005){#pone.0233804.g005}

In BLT, 11 of 23 (47.8%) patients were on extracorporeal membrane oxygenation (ECMO) on ICU arrival in the control group, 4 of 11 (36.4%) patients were on ECMO in the infiltration group with no significant difference between the 2 groups (*p* = 0.72). There was also no significant difference in ICU mortality between them (control group, 4 of 23, 17.4%; infiltration group, 1 of 11, 9.1%; *p* = 1.00). The mechanical ventilation period in the infiltration group was significantly longer than that in the control group (19.9 ± 12.9 vs. 41.9 ± 27.3 days, *p* = 0.009; [Fig 6A](#pone.0233804.g006){ref-type="fig"}). The ICU stay period in the infiltration group was also significantly longer than that in the control group (28.2 ± 15.0 vs. 54.3 ± 27.5 days, *p* = 0.004; [Fig 6B](#pone.0233804.g006){ref-type="fig"}). ICU mortality cases (control group, 4 cases; infiltration group, 1 case) were excluded from each group.

![Post-transplant mechanical ventilation period and ICU stay period in bilateral lung transplantation (BLT).\
(A) Mechanical ventilation period (days) in each group. The mechanical ventilation period in the BLT infiltration group was significantly longer than that in the BLT control group. (B) ICU stay period (days) in each group. The ICU stay period in the infiltration group was also significantly longer than that in the BLT control group. ICU mortality cases (control group, 4 cases; infiltration group, 1 case) were excluded from each group.](pone.0233804.g006){#pone.0233804.g006}

In SLT, 6 of 26 (23.1%) patients were on ECMO on ICU arrival in the control group, 2 of 10 (20.0%) patients were on ECMO in the infiltration group, with no significant difference between the 2 groups (*p* = 1.00). There was also no significant difference in ICU mortality between them (control group, 1 of 26, 3.8%; infiltration group, 1 of 10, 10.0%; *p* = 0.48). The mechanical ventilation period in the infiltration group was significantly longer than that in the control group (6.2 ± 5.7 vs. 11.9 ± 7.9 days, *p* = 0.03; [Fig 7A](#pone.0233804.g007){ref-type="fig"}). The ICU stay period in the infiltration group tended to be longer than that in the control group; however, the difference was not significant (12.3 ± 8.6 vs. 18.9 ± 8.2 days, *p* = 0.06; [Fig 7B](#pone.0233804.g007){ref-type="fig"}).

![Post-transplant mechanical ventilation period and ICU stay period in single lung transplantation (SLT).\
(A) Mechanical ventilation period (days) in each group. The mechanical ventilation period in the SLT infiltration group was significantly longer than that in the control group. (B) ICU stay period (days) in each group. The ICU stay period in the infiltration group tended to be longer than that in the control group; however, the difference was not significant. ICU mortality cases (control group, 1 case; infiltration group, 1 case) were excluded from each group.](pone.0233804.g007){#pone.0233804.g007}

[Fig 8](#pone.0233804.g008){ref-type="fig"} shows the proportion of patients with PGD grades 1 to 3 in the first 3 days after transplantation. The proportion of patients with PGD grades 1 to 3 in the BLT infiltration group was significantly higher than that in the BLT control group (*p* = 0.03). In other words, the improvement of the PGD grades in the BLT control group was significantly faster than that in the BLT infiltration group.

![Primary graft dysfunction grade in bilateral lung transplantation (BLT).\
Primary graft dysfunction (PGD) was graded according to the international society for heart and lung transplantation classification (ISHLT). \[[@pone.0233804.ref004]\] Grade 0 indicates the ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO~2~:FiO~2~) ≥300 mm Hg with clear chest radiographs; grade 1 PaO2:FiO2 ≥300 mm Hg with infiltration on chest radiographs; grade 2 PaO2:FiO2 ≥200 but \<300 mm Hg; and grade 3 PaO2:FiO2 \<200 mm Hg. This graph shows the proportion of patients with PGD grades 1 to 3 over time (first 3 days after transplantation) in BLT. The proportion of patients with PGD grades 1 to 3 in the infiltration group was significantly higher than that in the BLT control group (*p* = 0.03).](pone.0233804.g008){#pone.0233804.g008}

Discussion {#sec011}
==========

One of the ways to solve the problem of the waitlist mortality in lung transplantation is to maximize the lung utilization rate from marginal donors, such as donors with localized pneumonia or lung contusion. Moreno et al. reported that the use of extended criteria donors, including donors with pulmonary infiltrates on chest radiograph, did not increase the incidence of PGD or 30-day mortality. \[[@pone.0233804.ref005]\] Sundaresan et al. described that a mild infiltrate in one lung may be acceptable for bilateral lung transplants. \[[@pone.0233804.ref006]\] However, we must carefully evaluate the lung graft for a good outcome of the recipient.

One of the best methods to evaluate the infiltration of the donor lung is to take CT scans of the chest of the donor. In some donor cases, no chest CT scans are available and only chest X-rays are taken. Gauthier et al suggested that chest CT imaging might be an important adjunct to conventional lung donor assessment criteria. \[[@pone.0233804.ref007]\] Hoetzenecker also recommended routine chest CT scans of every donor for better judgement of the donor organ quality. \[[@pone.0233804.ref008]\] In fact, we can obtain CT scans of a potential lung donor and utilize the information accordingly. However, even if chest CT scans are available, these CT scans are not taken immediately before the retrieval in most cases. Such CT scans are important to detect structural lung diseases and decide the nonutilization of the lung graft. \[[@pone.0233804.ref007]\] On the other hand, we seldom obtain accurate information that reflects the acute abnormalities at the time of retrieval. In addition, whether the CT scans are taken immediately right before the retrieval or not, how specific CT findings in donors can affect recipient outcomes remain to be determined. \[[@pone.0233804.ref009]\]

In the present study, we demonstrated that EVL-CT provided us with detailed morphological information of the lung graft. Surprisingly, only in 5 of 11 cases (45.5%) in the BLT infiltration group and in 6 of 10 cases (60.0%) in the SLT infiltration group were infiltrates reported by chest X-rays of the donor before retrieval. The sensitivity of preretrieval chest X-ray was proven to be significantly low. In terms of specificity of preretrieval chest X-ray in the present study, in 20 of 23 cases (87.0%) of the BLT control group and in 24 of 26 cases (92.3%) of the SLT control group, no infiltrate was detected in the preretrieval chest X-ray. Vanstapel et al. demonstrated a histopathologic evaluation of the donor lungs declined for transplantation. They reported that 3 of 23 (13.0%) donor lungs that were not transplanted due to extrapulmonary causes displayed severe histologic abnormalities (pneumonia, emphysema) \[[@pone.0233804.ref010]\]. Similar to their study, 3 of 23 cases (13.0%) in the BLT control group and in 2 of 26 cases (7.7%) in the SLT control group showed infiltrations in EVL-CT in our study. We think that the preretrieval assessment of lung grafts by chest X-ray is unsatisfactory and EVL-CT may be one of the options to determine the utilization of the graft.

There are several reasons why EVL-CT revealed infiltrates in the lung graft. The most frequent reason in this study was pneumonia. We present a case in which EVL-CT revealed pneumonia in the donor ([Fig 5](#pone.0233804.g005){ref-type="fig"}). In this case, the information acquired in the EVL-CT was very useful for the subsequent postoperative management. Prior to our study, Verleden et al. reported the CT scans of frozen whole lungs revealed parenchymal infiltrates consistent with infection even in cases declined for transplantation due to non--allograft-related reasons. \[[@pone.0233804.ref003]\] Similar to their study, the EVL-CT in the present study allowed us to obtain additional information that had not be noticed upon the retrieval. In the present study, because EVL-CT was performed as a part of the clinical practice and all lungs were implanted to recipients, we were able to utilize the information for postoperative recipient care and investigate the outcome according to the results of EVL-CT.

One of the advantages of EVL-CT is that we can assess a lung graft that was adequately inflated on the retrieval and was without atelectasis. Indeed, whereas preretrieval CT images showed infiltrates in 4 of 6 donors in the BLT control group, the EVL-CT images revealed no infiltrates. Martens et al. states that current evaluation of donor lung quality at the time of the offer is often challenging and therefore the retrieval team should reevaluate the lungs when fully ventilated after the recruitment of atelectatic zones. \[[@pone.0233804.ref011]\] We believe that we can distinguish other types of infiltrates from atelectasis by taking EVL-CT of the donor lung because lungs are inflated well on the retrieval. In the present study, we took EVL-CT of the lung graft after arriving at our hospital and the transplant surgery was ongoing; therefore, the lung was implanted regardless the result of the EVL-CT. In the future, we could perform EVL-CT at the donor hospital and decide the acceptance of the lung graft with the data of donor arterial blood and the EVL-CT images.

Considering the severe condition and the long waiting time for the recipient, we sometimes must utilize lung grafts from a donor whose chest CT scans show infiltrates. Most of the donors in the infiltration group probably had mild pneumonia or acute bronchitis. In fact, bronchial aspirates in the culture were more often positive in the infiltration group than in the control group in both BLT and SLT. However, bronchial aspirates in the culture should be carefully interpreted because they do not always reflect organisms of the lower respiratory tract. \[[@pone.0233804.ref012]\] Other reasons for the finding of infiltration in EVL-CT included contusions due to chest trauma, and such infiltrations can easily be distinguished by the medical history of the donor.

Egan et al. reported a system of ex vivo evaluation of human lungs for transplant suitability in 2006. \[[@pone.0233804.ref013]\] In their study of 6 cases, ex vivo CT scans were obtained from human lungs deemed unsuitable for transplant. They stated that CT scan is a means to diagnose infiltrates and other abnormalities that might exclude lungs from being considered appropriate for transplantation. \[[@pone.0233804.ref013]\] In the present study, we present a series of 70 clinical lung transplant cases and demonstrated the simplicity and feasibility of EVL-CT. We also showed that, even though the ICU mortality was comparable, the improvement of PGD was slower and the mechanical ventilation period and ICU stay were longer in the BLT recipients who received lung graft with findings of infiltrates in EVL-CT. In addition, we demonstrated that the mechanical ventilation period was longer in the SLT recipients who received lung grafts with findings of infiltrates in EVL-CT. We believe that EVL-CT may predict the outcome of the early phase after lung transplantation.

There are several limitations in the present study. First, it was a retrospective single-center analysis with a small number of patients. Second, the EVLP technique that is currently in clinical use in some countries can assess the lung graft function ex vivo. On the other hand, whereas the EVL-CT used in the present study can provide us with morphological information of the lung graft, it cannot evaluate the function of the lung graft. Third, this was a non-interventional study and we did not change the following clinical practice based on the result of EVL-CT. As mentioned in Patients and Methods, at present we do not decide the availability of the lung graft based on the EVL-CT data. When we performed EVL-CT in the present study, the transplant surgery was already underway. We were not able to decline to use the lung graft for the lung transplant. Fourth, we were not able to completely eliminate selection bias. Due to the small number of patients, it was impossible to adjust for differences between the groups, for example propensity score-matching analysis.

In the future, we might be able to perform lobectomy on the back table according to the EVL-CT data in order to remove localized pneumonia or contusions, and then complete the lobar lung transplantation. As mentioned above, another future option may be performing EVL-CT at the donor hospital and decide the acceptance of the lung graft and then we start the lung transplant surgery of the recipient.

In conclusion, the BLT recipients who received lung graft with the findings of infiltrates in EVL-CT showed slower recovery from PGD and longer periods of mechanical ventilation and ICU stay than the BLT recipients without infiltrate. The mechanical ventilation period was significantly longer in the SLT recipients who received lung graft with findings of infiltrates in EVL-CT than in the SLT recipients without infiltrate. EVL-CT may predict the outcome of the early phase after lung transplantation.

The authors thank the radiological technologists of Tohoku University Hospital for their assistance with the collection of data. The authors would like to express their gratitude to Brent Bell for assistance in editing this manuscript.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
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ACADEMIC EDITOR:

Your MS has been highlighted by expert reviewers as novel and interesting, and therefore I invite you to thoroughly revise your paper according to the very helpful comments of my colleagues. Looking forward to seeing your revised MS.

==============================

We would appreciate receiving your revised manuscript by Apr 30 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.
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Academic Editor
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2\. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation.
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1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This is an interesting study, examining pre-implant CT scans of donor lungs. Previous similar reports have been of low numbers, so this is a novel study.

The references to EVLP are irrelevant, and could be removed -- this is a completely separate examination, and does not need to be compared with EVLP

It is made clear only in the discussion that the transplant was already underway when the CT was performed, so the results did not alter the decision to proceed. This information should come earlier in the manuscript

We are given results only in the cases undergoing CT scan. The data should be put in the context of the overall transplant programme. How did the donor choices and recipient outcomes differ, if at all, in the lungs not subjected to CT scan? How was the decision to perform the scan made? Were there different donor features?

The donor demographics do not contain donor blood gases, a widely used marker of donor quality. Is this data available? Did it differ in lungs with infiltrates?

The data comes from over 10 years of activity. How was it distributed in this time span? Ie were a lot of the scans done in the later part of the series? This again highlights the need to put the scanned patient in the whole context of the series.

There is a simple division of those lungs with infiltrates and those without. Whilst numbers were small, was any other analysis made of the infiltrates? Were they quantified? Was there any pattern linked to any particularly less good outcome?

The microbiology results are intriguing and potentially important. How were the bronchial aspirates obtained? Do they amount to a BAL, which properly samples organisms in the lung parenchyma? If so, was this guided by the CT? Or was it just an upper airway aspiration, where the findings are, in other series, less important. We presume this was not just a suction down the endotracheal tube in the donor, so effectively a tracheal rather than bronchial aspirates?

Reviewer \#2: This is a retrospective clinical study by investigators from Tohoku University in Sendai, Japan, investigating the value of ex-situ CT imaging of donor lungs immediately prior to lung transplantation.

The authors have investigated the correlation between abnormal findings on chest CT and early outcome after transplantation. They concluded that ex-situ CT imaging may help in evaluating donor lungs prior to acceptance for transplantation.

Major comments:

1\) Study period:

The authors studied 70 donor lung pairs over a period of 11 years (2007-2017). It would be interesting to know how many lung transplants were performed at their centre during the study period.

\- Did all donor lungs have CT imaging prior to transplantation? (70 transplants in eleven years is a very low annual number)

\- If not, how were the donor lungs selected to undergo CT imaging?

\- What happened to donor lungs that were already rejected for transplantation at the donor hospital? Where these lungs also recovered for CT imaging?

\- please discuss the selection of donor lungs in the paper and provide a study flow chart describing all donor offers over the study period with the number of lungs recovered, lungs scanned ex-situ with CT, and lungs transplanted.

2\) Terminology:

The authors have used the term "extracted donor lung (EDL) CT". The word "extracted" is not well choosen. The reviewer would prefer the term "ex-situ" donor lung CT imaging in contrast to "in-situ" donor lung imaging while the lungs are still inside the deceased donor body.

\- please change the terminology throughout the paper.

3\) CT scoring and reading by radiologist:

It is well known that reading of CT images is subjective with an important inter-observer variability.

\- How were the CT readers trained to describe findings of donor lungs on images taken outside the human body?

\- How many radiologist were involved in the study? How many looked at the images of 1 pair of donor lungs? Was there consensus on the findings amongst radiologists?

\- How did they do the scoring? Have they used a scoring system? How were the donor lungs assigned to one of both study groups?

\- Were the radiologist blinded to the macroscopic findings by the surgeon who retrieved the lungs?

\- Were there any lungs that were declined after reading the CT images?

\- Beside "infiltration", some of the donor lungs will have some underlying parenchymal disease (emphysema, interstitial fibrosis); Nothing is mentioned about parenchymal lung disease in the paper. See also paper by Gauthier et al (reference below). Was any underlying lung disease observed during imaging? Were these lungs excluded for transplantation?

Please describe in the methods in more details the technique and the number of radiologists involved in this study. Please discuss findings of underlying lung disease.

4\) PGD grading:

The ISHLT PGD grading system was first published by Christie et al in 2005 and then modified by Snell et al in 2017. The paper by Barr M et al (reference 4) does not discuss the PGD grading system!

\- Please describe which PGD grading system (2005 vs 2017) was used to score the lungs after transplantation and refer to the correct paper.

5\) Sensitivity and specificity of donor X-ray and CT scan:

The authors discuss in the paper that some of the donors had in-situ imaging in the days before retrieval. It is well known that standard X-ray imaging suffers from a low sensitivity and low specificity for abnormal findings. E.g. for the BLT group, the false positive rate was 13% and the false negative was 54.5% (see table 1). The accuracy of CT scan should be better. However, the false positive rate of CT scan in this series was still 66.7% (4/6; see Table 1).

\- the authors should discuss in this paper the sensitivity and specificity of standard X-ray and CT imaging based on other papers in the literature and correlate this with their own findings in the study.

\- it is important to stress that the cause of a "radiologic infiltrate" in donor lungs ranges from "pneumonia" to simple "atelectasis". Abnormal findings on the CT scan should always be checked inside the donor prior to declining a donor offer!! (see paper by Martens et al Eur J Cardiothorac Surg. 2016 Nov;50(5):832-833; Accepting donor lungs for transplant: let Lisa and Bob finish the job!)

6\) References:

The authors briefly discuss 4 papers (out of a total of only 10 references) whereby ex-situ MRI was used to correlate findings. These papers do not discuss the use of CT and do no refer to lung transplantation. The reviewer believes that all 4 references should be deleted.

On the other hand, there are more papers discussing the use of CT scan to evaluate donor lungs in-situ and ex-situ!

\- please discuss the following papers in the revised version:

Real-Time Computed Tomography Highlights Pulmonary Parenchymal Evolution During Ex Vivo Lung Reconditioning. Sage E, De Wolf J, Puyo P, Bonnette P, Glorion M, Salley N, Roux A, Liu N, Chapelier A. Ann Thorac Surg. 2017 Jun;103(6):e535-e537. doi: 10.1016/j.athoracsur.2016.12.02

Chest computed tomography imaging improves potential lung donor assessment. Gauthier JM, Bierhals AJ, Liu J, Balsara KR, Frederiksen C, Gremminger E, Hachem RR, Witt CA, Trulock EP, Byers DE, Yusen RD, Aguilar PR, Marklin G, Nava RG, Kozower BD, Pasque MK, Meyers BF, Patterson GA, Kreisel D, Puri V. J Thorac Cardiovasc Surg. 2019 Apr;157(4):1711-1718.e1. doi: 10.1016/j.jtcvs.2018.11.038.

Commentary: A plea for a donor CT! Hoetzenecker K. J Thorac Cardiovasc Surg. 2019 Apr;157(4):1720-1721. doi: 10.1016/j.jtcvs.2018.12.039. Epub 2018 Dec 21.

Minor comments:

7\) Figure legends:

\- Figure 2 and Figure 3: please correct the word "transactional" into "transaxial"

\- Figure 6 B: ICU stay was not significantly different in SLT! Please correct the word "significantly" in the sentence!

\- Figure 7: please refer in the legend to the correct reference for PGD grading.

8\) Tables 7& 8:

Both tables can be deleted; the data can be summarized in the text in the results section.

9\) Figure 7:

The current figure is difficult to interpret the differences between both groups. The reviewer believes that a survival curve showing "freedom from PGD3" would better depict the differences over time (T0-T72) between the control and the infiltration group.

Reviewer \#3: The objective of this study was to investigate the correlation between EDL-CT findings and post-transplant outcome in patients who underwent bilateral lung transplantation (BLT) or single lung transplantation (SLT).

Below are some comments:

1\. The nature of the study was exploratory. Allocation of control or infiltration group was not random and might depend on some variables which might or might not be directly recorded. Was there any methods applied to take into account such heterogeneity? Methods to compare the 2 groups with adjustments should be considered.

2\. Lines 234-235: As acknowledge by the authors due to the non-intervention nature, this study could not demonstrate the real practical usefulness of EDL-CT. How would you use the current information on EDL-CT from this study? Is there any plan for future research?

3\. In the article, it's not clear what was the primary endpoint for the study. Given the small sample sizes in both cohorts, the test statistics and the observed p-values should be interpreted carefully (including statements on significant difference etc). Apart from PGD and ICU mortality, has other endpoints such as a 30 mortality rate had ever been considered?

4\. How was the sample size and the power for this study determined? This should be clarified. If it is a convenient sample size, reasons to support such case should be underlined.

5\. The PGD grade at each time point was analyzed by repeated measures two-way ANOVA. As in point 1, please explain how the heterogeneity can be handled with this technique. Do you consider an alternative model to take into account heterogeneity of the different baseline factors when conducting this analysis?

6\. Lines: 226-227: 'CT. We believe that EDL-CT may predict the post-transplant outcome in lung transplantation.' Please provide evidence for this statement. Do you have any supporting data in the current study?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: John H Dark

Reviewer \#2: Yes: Dirk Van Raemdonck
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Thank you for making the changes as requested. I do agree with reviewer 3 to include a statement about the lack of sample size calculation, and to add a CONSORT diagram (patient seleciton/study groups). This will make the MS much more clear.
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To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.
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We look forward to receiving your revised manuscript.
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Academic Editor
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1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#2: Yes

Reviewer \#3: Yes
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3\. Has the statistical analysis been performed appropriately and rigorously?
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Reviewer \#3: Yes
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4\. Have the authors made all data underlying the findings in their manuscript fully available?
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Reviewer \#3: Yes
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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Reviewer \#3: Yes
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